HIM
ANIK icon

Hillsdale Investment Management’s Anika Therapeutics ANIK Stock Holding History

Hillsdale Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$368K Buy
+25,400
New +$295K 0.01% 449
2014
Q3 		– Sell
-6,900
Closed -$320K – 541
2014
Q2 		$320K Buy
+6,900
New +$307K 0.07% 200

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Hillsdale Investment Management's ANIK Position: Q1 2026 in Review

Hillsdale Investment Management opened a new position in Anika Therapeutics (ANIK) in Q1 2026: 25,400 shares worth $368K. The stake represents 0.01% of the portfolio and ranks #449 among its holdings. This is a return to the name: Hillsdale Investment Management previously reported a position in ANIK as recently as Q2 2014.

Hillsdale Investment Management first reported a position in ANIK in Q2 2014 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Hillsdale Investment Management held 25,400 shares of Anika Therapeutics worth $368K as of Q1 2026.
  • Anika Therapeutics was a new Hillsdale Investment Management position in Q1 2026.
  • Anika Therapeutics made up 0.01% of Hillsdale Investment Management's portfolio in Q1 2026, its #449 holding.
  • Hillsdale Investment Management first reported a position in Anika Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.